Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vir’s VIR-2482 Flunks In Phase II As Company Shifts Focus To Other Programs

Executive Summary

Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.

You may also be interested in...



Vir Biotechnology Decreases The Surplus Population

The beleaguered group is to cut its headcount and refocus on its hepatitis programs.

Several Options Remain For Cidara’s Flu Candidate After J&J Halts Development

Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.

Vir’s Hep B Combinations Could Bring Functional Cure To More Patients

The goal of reaching functional cure rates of up to 30% in hepatitis B now looks realistic, and Vir and GSK and others are racing to find the best combinations of novel and existing treatment options - new results at EASL this week will show how they are faring.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel